Sales and Marketing

Showing 15 posts of 11524 posts found.

Merck obesity drug to continue at low dose

April 11, 2008 Research and Development, Sales and Marketing

New data suggests Merck's taranabant drug can help obese patients lose weight, but safety concerns look to be behind higher …

Study confers protective benefits on Micardis

April 4, 2008 Sales and Marketing cv

Boehringer Ingelheim's hypertension treatment Micardis has come out on top of Aventis's gold standard ACE inhibitor Tritace in a new …

Trial fails to enhance Inegy’s prospects

April 4, 2008 Sales and Marketing cv

Schering-Plough and Merck's much-touted anti-cholesterol combination Inegy has suffered a setback following a poor showing in the ENHANCE trial. Inegy …

UCB’s Cimzia fails to appeal to European regulators

April 1, 2008 Sales and Marketing EU

UCB's Crohn's disease drug Cimzia has been denied European approval for a second time after regulators said lacked sufficient evidence …

Latest news from Datamonitor

March 31, 2008 Sales and Marketing

The impact of the US presidential race on healthcare IT The three leaders in the race for the US presidency; …

The role of audit in marketing excellence

March 28, 2008 Sales and Marketing audit, excellence, marketing

The goal for any business leader, whether they run a company, business unit or brand, should always be 100% alignment …

Gardasil licence extension gets priority FDA review

March 28, 2008 Sales and Marketing

Merck has received priority review status from the FDA for its application to extend the licence of its cervical cancer …

Accomplia gains limited NICE approval

March 28, 2008 Sales and Marketing

Sanofi-Aventis' weight-loss pill Acomplia has been approved for prescription on the NHS, but only for patients who fail to respond …

Merck’s hepatitis B vaccine trial on hold

March 28, 2008 Sales and Marketing

US regulators have placed a 'clinical hold' on one of the trials for Merck's hepatitis B vaccine Heplisav, raising questions …

Boehringer Ingelheim’s Pradaxa approved in Europe

March 28, 2008 Sales and Marketing

European regulators have approved Boehringer Ingelheim's novel anti-clotting pill Pradaxa, paving the way it to be launched in the coming …

Pharming’s orphan drug receives second setback in Europe

March 26, 2008 Sales and Marketing HAE, Pharming

Dutch biotech company Pharming has suffered a blow, after its lead product Rhucin was rejected by European regulators for a …

Latest news from Datamonitor

March 25, 2008 Sales and Marketing em

Faced with dwindling growth rates in the US and Europe, drug companies are turning their attention towards emerging pharmaceutical markets …

Early access to experimental drugs for terminally ill

March 25, 2008 Sales and Marketing

Terminally ill cancer patients are to get early access to developmental drugs in a bid to halve the time it …

Latest news from Datamonitor

March 20, 2008 Sales and Marketing

With pharmaceutical companies struggling to maintain pipelines and portfolios with products developed in-house, organizations are increasingly turning to licensing to …
The Gateway to Local Adoption Series

Latest content